NEWS & MEDIA
2025 International Society of Liquid Biopsy Young Investigator Award
Dr. Berchuck was selected for this award for his work on Multimodal cfDNA profiling to predict response and resistance to tarlatamab in small cell lung cancer.
2025 Prostate Cancer Foundation Young Investigator Award
Dr. Berchuck was selected for this award for his work on Integrated profiling of spatial and circulating biomarkers to optimize precision therapy in advanced prostate cancer.
Understanding Resistance to PSMA-Targeted Therapy in Metastatic Prostate Cancer
Dr. Berchuck discusses novel research findings presented at ASCO 2025 pointing to androgen receptor signaling and Wnt pathway activation as key correlates of poor response to Lutetium-PSMA in patients with advanced prostate cancer.
Best Poster Award at the 2024 International Society of Liquid Biopsy Annual Congress
A research study led by Dr. Berchuck, entitled “Determination of Tumor PSMA Expression and Lutetium-PSMA Response in Men With Prostate Cancer Using a Novel Epigenomic Liquid Biopsy Platform” was awarded Best Poster at the International Society of Liquid Biopsy (ISLB) 2024 Annual Congress.
Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPC
Dr. Berchuck joins OncLive to discuss the ability of a novel epigenomic liquid biopsy platform to noninvasively detect prostate-specific maturation antigen (PSMA) expression in metastatic castration-resistant prostate cancer (mCRPC), according to results from a study presented at the 2024 ESMO Congress.
Novel Epigenomic Liquid Biopsy Detects PSMA Expression in Prostate Cancer
Dr. Oliver Sartor hosts Dr. Berchuck to discuss a novel epigenomic liquid biopsy platform for determining PSMA expression in prostate cancer. They explore the potential of this technology to provide real-time, non-invasive monitoring of tumor drug target expression, which could guide treatment decisions for various cell surface-targeting therapies. The conversation explores future applications, including tracking treatment response, understanding resistance mechanisms, and discovering new molecular subtypes.
Epigenomic Liquid Biopsy for Detecting Tumor PSMA in Prostate Cancer
Dr. Berchuck joins Targeted Oncology to discuss results and implications of his poster as ESMO 2024 on “Determination of tumor PSMA expression in prostate cancer from blood using a novel epigenomic liquid biopsy platform.”
Ask the Expert: Navigation Tools for Prostate Cancer Diagnosis and Treatment
In this Q&A session with Outcomes4Me for National Men’s Health Month, Dr. Berchuck provides insights into cutting-edge therapies, recent clinical trials, and emerging research that are shaping the future of prostate cancer detection and care. Dr. Berchuck covers a range of topics, including crucial aspects of diagnosing prostate cancer, early warning signs, the latest in genetic testing, and how personalized medicine is enhancing detection and treatment strategies.
Prostate Cancer Conference Highlights: ASCO Genitourinary Cancers Symposium 2024
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ASCO GU 2024 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Prostate Cancer Conference Highlights: ASCO Annual Meeting 2023
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ASCO 2023 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Prostate Cancer Conference Highlights: ASCO Genitourinary Cancers Symposium 2023
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ASCO GU 2023 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Elucidating Differential Androgen Receptor Cistromes in African American versus European American Men
Dr. Berchuck shares insights from his research on racial disparities in prostate cancer. Dr. Berchuck’s study explores the androgen receptor cistrome and its differing effects on prostate cancer biology in African American and European American men.
Prostate Cancer Conference Highlights: ESMO Congress 2022
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ESMO 2022 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Prostate Cancer Conference Highlights: ASCO Annual Meeting 2022
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ASCO 2022 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Prostate Cancer Conference Highlights: ASCO Genitourinary Cancers Symposium 2022
Dr. Berchuck presents a summary of all the prostate cancer clinical updates you need to know from ASCO GU 2022 at the Dana-Farber Cancer Institute Lank Center for Genitourinary Oncology Conference Highlights Seminar.
Expert Opinion: Androgen Indifferent Prostate Cancer
Dr. Berchuck discusses clinical considerations for the management of androgen indifferent prostate cancer with DocWire News.
Genetic Risk in Prostate Cancer
Dr. Berchuck and Dr. Mary-Ellen Taplin discuss genetic risk in localized high-risk prostate cancer, nuances of genetic testing, and the impact of germline DNA alterations for men with prostate cancer.